On Thursday, Shares of Intel Corporation (NASDAQ:INTC), gained 0.10% to $29.27.
Intel Corporation declared a 10-year collaborative relationship with the Delft University of Technology and TNO, the Dutch Organization for Applied Research, to accelerate advancements in quantum computing. To achieve this aim, Intel will invest US$50 million and will provide noteworthy engineering resources both on-site and at Intel, in addition to technical support.
Quantum computing holds the promise of solving complex problems that are practically insurmountable recently, counting intricate simulations such as large-scale financial analysis and more effective drug development. Quantum computing is an area of research that Intel has been exploring because it has the potential to augment the capabilities of tomorrow’s high performance computers.
Intel’s aim is to extend the university’s physics expertise and diverse quantum computing research efforts by contributing advanced manufacturing, electronics and architectural expertise.
Intel Corporation designs, manufactures, and sells integrated digital technology platforms worldwide. It operates through PC Client Group, Data Center Group, Internet of Things Group, Mobile and Communications Group, Software and Services, and All Other segments.
Shares of Twenty-First Century Fox, Inc. (NASDAQ:FOXA), inclined 0.11% to $26.51, during its last trading session.
The National Geographic Society and 21st Century Fox declared recently that they have reached a contract to expand their highly successful 18-year partnership through which they have owned and operated the properties in National Geographic Channels, a joint venture of domestic and international cable television channels which together reach more than 500 million households globally.
The National Geographic Society is a 501(c)(3) non-profit organization focused on its mission of science, exploration and education. Consideration for the transaction is valued at $725 million. As a result, the Society’s endowment will significantly improvement to nearly $1 billion. The new entity will be owned 73 percent by 21st Century Fox and 27 percent by The National Geographic Society with a shared governance structure and equal representation on the board of directors. The Board Chair will alternate annually, with Gary Knell, National Geographic Society President and CEO, serving as the Board’s first Chairman.
The new expanded joint venture will operate as National Geographic Partners and will combine the National Geographic television channels with National Geographic’s other media and consumer-oriented assets, counting: National Geographic magazines; National Geographic Studios; related digital and social media platforms; books; maps; children’s media; and ancillary activities, counting travel, location-based entertainment, archival sales, catalog, licensing and ecommerce businesses. Combining these assets into one organization will create greater opportunities to pursue National Geographic’s mission of increasing knowledge through science, exploration, and research.
Declan Moore, a 20-year veteran of the Society presently serving as Chief Media Officer, has been designated CEO of National Geographic Partners.
Twenty-First Century Fox, Inc. operates as a diversified media and entertainment company worldwide. It operates through Cable Network Programming; Television; Filmed Entertainment; and Other, Corporate and Eliminations segments.
Finally, Boston Scientific Corporation (NYSE:BSX), ended its last trade with 0.90% gain, and closed at $16.78.
Boston Scientific Corporation has received CE Mark for the Vercise™ Primary Cell (PC) Deep Brain Stimulation (DBS) System. The Vercise PC System is intended to provide precise neural targeting to address the varying needs of patients suffering from Parkinson’s disease (PD), primary and secondary dystonia, and essential tremor. The System is a non-rechargeable treatment option that also powers the Vercise DBS Directional Lead, the first commercially available eight-contact segmented lead with current steering.
The Vercise platform is the only DBS solution that finely controls the size and shape of stimulation with multiple independent current control technology (MICC). The new Directional Lead with MICC produces multi-directional stimulation which improvements target efficiency. The system comprises unique software solutions with a Clinical Effects Map (CEM) that captures data over time, visually summarizes the progress of individualized patient therapy, and enables physicians to monitor and modify treatment as needed. These novel features allow for programming flexibility, designed to enable better outcomes with fewer side effects.
“Managing the side effects of unwanted stimulation while delivering effective therapy is one of the biggest challenges of DBS,” said Prof. Dr. Jens Volkmann, director and chairman of the Department of Neurology, University Hospital of Würzburg. “The distinctive software solution of the new Vercise platform is straightforward yet intuitive and can assist address this challenge.”
DBS therapy involves the placement of a device that stimulates specific areas in the brain using electrical signals. The Vercise PC System supplements the company’s rechargeable DBS device, a system with an unparalleled 25-year battery life.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Administration, and MedSurg.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
